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Objectives: Giant cell arteritis (GCA) is the most frequent primary large-vessel 
vasculitis in patients aged over 50 years. Common early manifestations include 
constitutional symptoms, headache, visual loss, polymyalgia rheumatica (PMR), and 
jaw claudication. The incidence increases with age and is higher in populations of 
Northern European origin than in those of Mediterranean countries. The incidence 
of GCA in France is 10 to 20 per 100 000 people older than 50 years. The aim of this 
study is to assess the net costs due to GCA in France and to identify driver costs of 
this disease. MethOds: This retrospective study used an incidence based approach. 
Incident GCA patients were identified in the French National Health Insurance 
System database (SNIIR-AM) from 2005 to 2008. For each case, 6 disease-free age 
and gender matched-controls were randomly selected. Their resources consump-
tion was recorded over a 5 years period. Costs were estimated from the health 
insurance perspective. Direct medical, non-medical and indirect costs (i.e. daily 
benefits) were recorded. GCA patient’s costs were compared to control’s costs then 
we calculated GCA net costs. Results: 103 GCA patients and 606 control patients 
were included. In the first year following the diagnosis, GCA patient’s costs were 
8,139€ and control’s costs were 3,661€ (p< 0.001), the net GCA costs was 4,478€ . 
This incremental cost was mainly due to inpatients, medications and paramedical 
costs which accounted for 40%, 17% and 16%, respectively. GCA and controls costs 
decreased during the 5 year follow-up period from 8,139€ year one to 4,572€ year 
five for GCA and from 3,661€ to 3,054€ for controls. cOnclusiOns: GCA constitutes 
a huge economic burden in health insurance expenses.
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Objectives: Chronic heart failure (CHF) is a progressive, debilitating disease where 
the heart is unable to pump enough blood throughout the body. In a recent trial, 
LCZ 696, a novel combination drug, showed significantly reduced mortality and 
heart failure hospitalisations compared with enalapril for the treatment of patients 
with CHF. The objective of this study was to systematically identify and quantify 
the non-health sector costs for adults with CHF and in caregivers to patients with 
CHF. MethOds: Embase, Medline, Cochrane Library and relevant conferences and 
HTA databases were searched systematically in July 2014 to identify articles contain-
ing CHF populations with any data on indirect or direct cost/resource use that did 
not fall on the health care budget was collected. There was no restriction on inter-
vention or comparator. Results: In total, seven studies were identified that met the 
inclusion criteria of the review. Three studies reported direct costs that do not fall 
on the health care budget and two studies reported indirect costs incurred by heart 
failure patients and their caregivers. No studies could be considered generalizable 
to the UK perspective. The societal cost evidence identified in this review included 
patient out-of-pocket expenses (US, Brazil, Taiwan, Spain), number of work days 
lost for patients (US, Brazil), hours of care provided from informal caregivers (Iran, 
Spain, Taiwan, Australia), and sick leave (US, Brazil) associated with hospitalization 
for heart failure events. Only scarce information pertaining to direct non-health 
care sector costs (caregiver time and patient out-of-pocket expenses), and indirect 
effects on the rest of the economy (sick leave, attendee and patient working days 
lost) were reported. cOnclusiOns: In summary, this review highlights the paucity 
of available societal cost evidence for patients with chronic heart failure. Further 
studies are needed to address this knowledge gap.
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Objectives: This study evaluated the economic burden associated with new car-
diovascular events (CVEs) for 3 years post-CVE among high-risk patients diagnosed 
with hyperlipidemia. MethOds: A retrospective cohort study was conducted 
among high-risk hyperlipidemic patients with and without a new CVE, using IMS 
LifeLink PharMetrics Plus data 01/01/2006-06/30/2012. CVEs included primary inpa-
tient claims for myocardial infarction, unstable angina, ischemic stroke, transient 
ischemic attack, revascularization and heart failure. Patients were assigned to 
risk cohorts based on history of CVE and coronary heart disease risk equivalent 
(CHD RE) condition. Propensity score matching was applied to compare healthcare 
costs among patients with and without new CVEs, ranging from 1 month (acute 
phase) to 3 years post-CVE date. Results: A total of 21,482 matched patients 
were included in the history of CVE cohort and 181,228 in the CHD RE cohort. 
Hyperlipidemic patients with new CVEs were, on average, aged 65-72 years, both 
cohorts had 65.2% male and 74.7-84.4% had hypertension (most common baseline 
comorbidity). Total costs per patient per month (PPPM) were significantly higher 
among patients with versus without new CVEs during the acute phase (history of 
CVE: $27,247 vs. $1,586; CHD RE: $30,742 vs. $914; p< 0.0001) and remained higher 
during years 1, 2 and 3, respectively, post-CVE among patients in the history of CVE 
cohort ($2,603 vs. $1,252; $2,055 vs. $1,191; $2,061 vs. $1,166, p< 0.0001) and CHD RE 
cohort ($1,926 vs. $844; $1,535 vs. $850; $1,475 vs. $853, p< 0.0001). Significant cost 
differences were observed between patients with and without new CVEs in both 
cohorts, including inpatient, outpatient, emergency room and pharmacy visit costs 
PPPM, during 1-3 years post-CVE. cOnclusiOns: Healthcare costs for high-risk 
patients with new CVEs remained significantly higher than for matched patients 
Objectives: To estimate acute, short-term and long-term healthcare costs among 
hyperlipidemia patients following a cardiovascular event (CVE). MethOds: This 
retrospective cohort study examined hyperlipidemia patients (≥ 1 medical claim 
and/or ≥ 1 prescription for lipid-lowering therapy) using longitudinal administrative 
claims data from a large commercial US insurer. Those with a CVE and those without 
a CVE were propensity score matched to adjust for differences in demographics, 
comorbidities, and coronary heart disease risk. Qualifying CVEs were MI, ischemic 
stroke, PCI, CABG, unstable angina, TIA or heart failure. Patients were followed from 
index (date of first CVE or a randomly selected date for those w/o a new CVE) until 
the earlier of disenrollment, 8/31/12, or 36 months after the index. Analyses reported 
here are limited to commercially enrolled CVE patients and their matched no CVE 
pair. The payer perspective was taken for all analyses with cost representing the 
total health plan + patient paid amounts. Mean ±SD costs are presented for the 
following periods: acute (days 0-30), short-term (days 31 to 365), 2nd year (days 366-
730) and 3rd year (days 731-1095). Results: The study included 156,679 pairs. Acute 
costs were $23,213±41,561 and largely driven by inpatient costs ($18,040±39,805). 
Acute costs among those with no CVE were significantly less at $799±4,037 (p< 0.001). 
Costs in the short-term were $18,532±48,721 ($6,484±15,948 for no CVE, p< 0.001), 
2nd year costs were $15,335±43,438 ($4,396±13,326 for no CVE, p< 0.001) and 3rd year 
costs were $14,210±38,681 ($2,704±9,783 for no CVE, p< 0.001). cOnclusiOns: Acute 
costs are highest in hyperlipidemia patients with a CVE compared to those without. 
The main driver of costs following a CVE was inpatient hospitalizations. Although 
costs decline in the short- and long-term, costs of patients with CVEs remain high 
for several years compared to hyperlipidemia patients without CVEs.
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Objectives: To quantify the cost savings potential due to a reduction in hos-
pitalizations (all-cause and for worsening HF) for patients with chronic systolic 
HF. MethOds: An economic model was developed to quantify the rates and costs of 
hospitalizations from both the US commercial (< 65 years of age) payer and Medicare 
perspectives in patients with chronic systolic heart failure. Hospitalization rates 
and costs by hospitalization type were taken from US commercial and Medicare 
claims data. The SHIfT trial was used to obtain rate ratios by type for hospitaliza-
tion of patients receiving ivabradine versus placebo on a background of guideline-
suggested drug therapy. A generalized linear model with Poisson distribution and 
log-link function was used to estimate admission rate ratios adjusted for baseline 
beta-blocker use. Results: In the commercial HF population, an annual rate of 
all-cause hospitalization of 1.52 per patient-year (PY) results in a cost burden of 
$46,215/PY; 75% of that cost is from HF-related hospitalizations. The rate ratios and 
95% confidence intervals with ivabradine over the entire trial follow-up were: 0.74 
(0.68-0.80) and 0.89 (0.82-0.96) for HF-related and all-cause hospitalizations, respec-
tively. With ivabradine, a reduction of $9,980/PY in all-cause hospitalization costs 
was estimated in the commercially insured HF population, $8,904 of which was due 
to reductions in HF-related hospitalizations. A higher rate of hospitalization in the 
Medicare population was observed (2.19/PY), but was associated with a lower cost 
burden of $29,982/PY due to lower cost per hospitalization. With the same relative 
risk reduction, ivabradine yielded a $4,627/PY reduction in all-cause hospitaliza-
tion costs in the Medicare population, $3,207/PY of which was due to reductions 
in HF-related hospitalizations. cOnclusiOns: The cost burden of hospitalization 
events is substantial for patients with HF. Reducing the rate of hospitalizations 
with ivabradine may reduce hospitalization costs by $9,980/PY and $4,627/PY for 
the commercially insured and Medicare population, respectively.
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Objectives: To describe the healthcare resource utilization and costs in the year 
following hospitalization for acute ischemic stroke (AIS). The mean lifetime cost 
of AIS is approximately $140,000. With cost estimates projected to increase three-
fold by 2020, it is important to gain a better understanding of the direct economic 
burden of AIS in the US. MethOds: The MarketScan® Commercial Database was 
used to identify non-elderly adults (age 18-64) hospitalized with AIS (index defined 
as first Medicare Severity Diagnosis Related Group 061-066 and confirmatory AIS 
diagnosis (ICD-9-CM: 434.x1)) between January 2009 and December 2012. Patients 
were required to have 12 months of continuous enrollment pre- and post-index. 
Patients with AIS in the year pre-index were excluded. Demographic and clini-
cal characteristics were evaluated at admission and in the pre-index, respectively. 
Direct costs, inpatient length of stay (LOS) and readmissions were described in the 
year post-index. Results: A total of 20,314 patients (age= 54.1 years (standard 
deviation (SD)= 7.9); 57.9% male) met all selection criteria. Approximately one-half 
(46.9%) of patients had baseline hypertension and one-fourth had hyperlipidemia 
(27.2%) and diabetes (25.7%). Total mean costs for the index AIS admission were 
$18,456 (SD= $30,549) with an average LOS of 3.8 days (SD= 4.5). Mean all-cause 
costs in the year after an AIS were $61,354 (SD= $83,048), one-half of which were 
incurred 31-365 days following the incident AIS. One-fourth (24.6%) of patients were 
readmitted within 30 days, 16.6% of those readmitted had a principal diagnosis of 
AIS with an average LOS nearly three times that of the initial hospitalization (10.8 
days (SD= 18.7)). cOnclusiOns: In addition to the substantial costs of the initial 
hospitalization of an acute ischemic stroke, these costs double within the year 
following this event. Given the high cost associated with AIS, new interventions 
reducing either the acute or longer term burden of AIS are needed.
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49,9%, lipid–lowering 22,7% and Antidiabetics the 6,1% of the total annual follow 
up medication cost . For the patients were subjected to ICD initial implantation 
antiplatelet–anticoagulants represent 24,4 %, antiarrhythmic 2,2 %, cardiovascular 
44,2 %, lipid–lowering 25,0% and antidiabetics 4,1% of the total annual follow up 
medication cost. For the patients were subjected to ICD replacement antiplate-
let–anticoagulants represent the 28,7 %, antiarrhythmic the 7,7 %, Cardiovascular 
58,1 %, Lipid–lowering 5,5% and Antidiabetics 0,0% of the total annual follow up 
medication cost . cOnclusiOns: The present study provides unique data regard-
ing the percentage of annual medication cost attributed to each kind of treatment 
of unselected patients subjected to CRMDs implantation in a real-world setting.
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Objectives: To estimate the cost-effectiveness of strategies for treatment deep 
vein thrombosis (DVT), the primary objective was to compare of effects of catheter-
directed thrombolysis (CDT) and anticoagulation versus anticoagulation in the man-
agement of people with DVT of the lower limb. DVT occurs when a blood clot forms 
in a leg vein. The clot can break up and move to the lungs, leading to a potentially 
serious blockage in blood flow (pulmonary embolism). Because of the damage to 
the leg vein, post-thrombotic syndrome (PTS) may develop any time over the next 
couple of years. MethOds: We used a Markov state transition decision model to 
evaluate the cost-effectiveness of treatment strategies using a societal perspective 
for costs, effectiveness-measured in incremental cost-effectiveness. Data sources 
included the English language literature using MEDLINE searches and bibliographies 
from selected articles. Results: Our study showed that CDT may have advan-
tages over standard anticoagulation treatment. CDT effectively dissolved the clot 
so that complete clot breakdown occurred more often with CDT than with standard 
anticoagulant therapy. CDT and anticoagulation with compression stockings was 
associated with an effectiveness of 21.67 QALYs and a lifetime cost of $48 442. The 
incremental cost-effectiveness ratio (ICER) was $14 728/QALY gained. CDT increases 
the patency of veins and reduces the incidence of PTS following DVT by 35%. Strict 
eligibility criteria are necessary to reduce the risk of bleeding complications and this 
limits the applicability of this treatment. cOnclusiOns: CDT and anticoagulation 
are highly cost-effective strategies for treatment patients with DVT and a low risk of 
bleeding. Use of strict eligibility criteria has improved the safety and acceptability 
of this treatment, with treatment directed by catheter in more extensive clots now 
the favoured method.
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Objectives: To evaluate the economic value of dabigatran in the treatment of 
deep vein thrombosis (DVT), pulmonary embolism (PE) and prevention of recur-
rent events in comparison with other reimbursed oral anticoagulants warfarin 
and rivaroxaban from a perspective of Mexican public institutions. MethOds: A 
Markov disease model with one month cycles length was developed. A number 
of parameters were followed in the model within the lifetime horizon (mean 18.2 
years from diagnosis for Mexican patients), including efficacy and safety relevant 
events and treatment related costs. Main modelling outcome was life-years gained. 
Identical hypothetical cohorts of patients entered the model, following either 
acute index DVT or PE (500 simulations per treatment arm). Modelled efficacy 
endpoints (recurrent venous thromboembolic events, including DVT, fatal and 
non-fatal PE), safety endpoints (major and clinically relevant non-major bleeds) 
and treatment related adverse events were utilized from published results of head 
to head clinical trials or derived in network meta-analysis and indirect compari-
sons. Public institutional direct medical costs (2014 purchases and price tabulators) 
where retrieved to adopt the national health system perspective. Results: Mean 
life-years saved for dabigatran, warfarin and rivaroxaban were 4.478, 4.475 and 
4.476 respectively. The highest cost of treatment was reported by rivaroxaban with 
7,959.15 USD, followed by warfarin (7,923.31 USD) and dabigatran (7,748.46 USD). 
ICER showed dabigatran is a dominant alternative versus both rivaroxaban and 
warfarin. Results were robust to changes in discount rates. Dabigatran remained 
as a dominant alternative versus rivaroxaban and as a cost-effective one ver-
sus warfarin, in a price sensitivity analysis. cOnclusiOns: From a perspective 
of Mexican public institutions, the treatment with dabigatran resulted to be a 
cost-saving alternative that could potentially increase life-years gained without 
increasing health care spends.
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Objectives: Atrial fibrillation (AF) is the most common cardiac rhythm disorder; it 
increases stroke risk 5 to 6 times. Prevalence in Colombia has been estimated in 3.6% 
in population age 60 or over (some 180 000 potential patients). The aim of this study 
was to estimate cost-effectiveness of dabigatran 110 mg and 150 mg BID as a therapy 
for non valvular AF in Colombian population. MethOds: From a third-party payer 
perspective (Colombian health system) we used a three-month cycle Markov model 
with six health states (and death): non-disabling stroke, disabling stroke, acute myo-
cardial infarction and pulmonary embolism; two additional events were transient 
states: minor and mayor bleeding. Transition probabilities and proportion of events 
without CVEs for up to 3 years post-CVE, imposing a significant economic burden 
on U.S. commercial payers.
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Objectives: Previous studies estimate that up to 15% of patients who undergo 
cardiovascular surgery require reoperation due to bleeding. The objective of this 
study is to estimate the incremental cost to hospitals for reoperations where a 
bleeding event is the primary reason across cardiovascular reconstructive surger-
ies. MethOds: The study identified patients age 18 years or older with a record in 
the Premier hospital database between January 1, 2010 to September 30, 2012 who 
underwent cardiovascular reconstructive surgery. An algorithm (clinician expert 
rules and Premier Chargemaster data) was developed to define a reoperation where 
a bleeding event is the primary reason. Patients were excluded from analysis if 
extracorporeal circulation was utilized during the reoperation. The final sample 
included 294,548 patients in seven procedure groups: CABG, valve repair/replace-
ment, AAA repair, AV access, endarterectomy, femoral-femoral/femoral-popliteal 
bypass, and other vascular. Multivariable modeling was performed to estimate the 
incremental effect on hospital costs for bleeding events that required reoperation. 
Regression models to control for age, gender, race, marital status, insurance type, 
and severity and mortality risk were performed for each category of cardiac and 
vascular reconstructive surgery. Results: Descriptive results indicated that aver-
age hospital visit costs with no reoperation ranged between $10,832 [SD $10,731] 
and $48,768 [$28,368] depending on the procedure. The incremental additional cost 
per visit associated with a reoperation surgery for bleeding is estimated as follows 
by procedure group: CABG $30,951[$1,431]; valve repair $27,037 [$2,124]; AAA repair 
$30,145 [$1,235]; AV access $11,996 [$1,073]; endarterectomy $18,645 [$512]; fem-fem/
fem-pop bypass $44,383 [$1,699], and other vascular $25,861 [$432]. cOnclusiOns: 
The incremental cost of reoperations for bleeding events in cardiac and vascular 
reconstructive surgery varied between 63% and 179% depending on the procedure 
group, with the largest increase for femoral-femoral bypass procedures, CABG, AAA 
repair, and valve procedures respectively.
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Objectives: The objective of this investigation was to compare the contrasting 
results of recent cost-effectiveness analyses of statins. MethOds: A systematic 
review of the literature on statin cost-effectiveness was conducted as per Cochrane 
methodology. Results: The four studies that met inclusion criteria reported vari-
able conclusions about the cost-effectiveness of statin treatment, without a clear 
unanimity as to whether statins are cost-effective for primary prevention. All stud-
ies analyzed health care costs from the health care system perspective – inclusive of 
and limited to all direct medical costs to all payers resulting from the statin therapy. 
The time horizon varied from as 5 years to lifetime. Annual drug prices ranged 
from $770 to over $1,500 in 2006 dollars. The studies reported varying assessments 
of the cost-effectiveness of statins. Costs ranged from $590,000 to $3 to extend 
life by one year. Recently published studies found statin therapy more likely to be 
cost-effective. However, when each study’s assumptions about statin costs were 
accounted, a substantial agreement among the authors was observed. Studies 
which assumed statins to be more costly found them to be less cost-effective, and 
vice-versa. Moreover, treatment of the lower risk groups appeared cost-effective as 
statins became cheaper. The studies were appraised using Philips and NICE checklist 
(qualitatively) and Quality of health economic studies (quantitatively). The studies 
were found to be of average quality. cOnclusiOns: As the statins become generic, 
the chances of the patients at low risk for coronary disease may be treated cost-
effectively increases. It would be thus reasonable for clinicians to treat low-risk 
patients and statin therapy for a broader patient base, based on cost-effectiveness.
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Objectives: To estimate the percentage of annual follow up medication cost attrib-
uted to each kind of treatment of unselected patients subjected to CRMDs implan-
tation in a real-world setting. MethOds: During a period of one year in total 464 
(370 were subjected to PM implantation, 240 initial, 130 replacement and 94 to ICD 
implantation, 80 initial, 14 replacement) consecutive recipients were subjected to 
CRMD’s implantation and furthermore were recruited and followed up for 1 year. At 
six and twelve months after the procedure of implantation we record the medica-
tion use for each patient. Results: For the patients were subjected in PM initial 
implantation antiplatelet–anticoagulants represent 24,5%, antiarrhythmic 1,1,%, 
cardiovascular 47,8%, lipid–lowering 22,6% and antidiabetics 3,9% of the total annual 
follow up medication cost. For the patients were subjected to PM replacement anti-
platelet–anticoagulants represent 19,6%%, antiarrhythmic 1,7%, cardiovascular 
